A new meta-analysis study looking at prior studies of PARP inhibitors in patients with metastatic castration-resistant prostate cancer and an inherited gene mutation showed:
- the greatest benefit in BRCA carriers
- a strong signal of benefit in PALB2 or CDK12 alterations
- no benefit in ATM or CHEK2 carriers
Learn more at: https://pubmed.ncbi.nlm.nih.gov/39848867/
Reference: Naqvi, et al. Eur Urol. 2025:S0302-2838(24)02760-X. PMID: 39848867.